Literature DB >> 34791392

Translational Aspects of the Immunology of Clostridioides difficile Infection: Implications for Pediatric Populations.

Larry K Kociolek1,2, Joseph P Zackular3,4,5, Tor Savidge6.   

Abstract

Clostridioides difficile has become the most common healthcare-associated pathogen in the United States, leading the US Centers for Disease Control and Prevention (CDC) to classify C. difficile as an "urgent" public health threat that requires "urgent and aggressive action." This call to action has led to new discoveries that have advanced our understanding of Clostridioides difficile infection (CDI) immunology and clinical development of immunologic-based therapies for CDI prevention. However, CDI immunology research has been limited in pediatric populations, and several unanswered questions remain regarding the function of host immune response in pediatric CDI pathogenesis and the potential role of immunologic-based therapies in children. This review summarizes the innate and adaptive immune responses previously characterized in animals and humans and provides a current update on clinical development of immunologic-based therapies for CDI prevention in adults and children. These data inform the future research needs for children.
© The Author(s) 2021. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 C. difficilezzm321990 ; antibody; immunity; pediatric; vaccine

Mesh：

Year:  2021        PMID： 34791392      PMCID： PMC8600028          DOI： 10.1093/jpids/piab089

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   5.235


  61 in total

1.  Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.

Authors:  J Salcedo; S Keates; C Pothoulakis; M Warny; I Castagliuolo; J T LaMont; C P Kelly
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

2.  Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.

Authors:  Guy de Bruyn; David L Gordon; Theodore Steiner; Paul Tambyah; Catherine Cosgrove; Mark Martens; Ehab Bassily; Eng-Soon Chan; Dhaval Patel; Josh Chen; Julian Torre-Cisneros; Carlos Fernando De Magalhães Francesconi; Richard Gesser; Robert Jeanfreau; Odile Launay; Thelma Laot; Rayo Morfin-Otero; Ernesto Oviedo-Orta; Yoon Soo Park; Franco M Piazza; Christine Rehm; Enrique Rivas; Steve Self; Sanjay Gurunathan
Journal:  Lancet Infect Dis       Date:  2020-09-15       Impact factor: 25.071

3.  High colonization rate and prolonged shedding of Clostridium difficile in pediatric oncology patients.

Authors:  Samuel R Dominguez; Susan A Dolan; Kelly West; Raymund B Dantes; Erin Epson; Deborah Friedman; Cynthia A Littlehorn; Lesley E Arms; Karen Walton; Ellen Servetar; Daniel N Frank; Cassandra V Kotter; Elaine Dowell; Carolyn V Gould; Joanne M Hilden; James K Todd
Journal:  Clin Infect Dis       Date:  2014-04-29       Impact factor: 9.079

4.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

5.  Effects of nitric oxide and reactive oxygen species on HIF-1α stabilization following clostridium difficile toxin exposure of the Caco-2 epithelial cell line.

Authors:  Joshua Y Lee; Simon A Hirota; Louise E Glover; Glen D Armstrong; Paul L Beck; Justin A MacDonald
Journal:  Cell Physiol Biochem       Date:  2013-08-27

6.  Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease.

Authors:  S Johnson; W D Sypura; D N Gerding; S L Ewing; E N Janoff
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

7.  IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection.

Authors:  Alyse L Frisbee; Mahmoud M Saleh; Mary K Young; Jhansi L Leslie; Morgan E Simpson; Mayuresh M Abhyankar; Carrie A Cowardin; Jennie Z Ma; Patcharin Pramoonjago; Stephen D Turner; Alice P Liou; Erica L Buonomo; William A Petri
Journal:  Nat Commun       Date:  2019-06-20       Impact factor: 14.919

8.  A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.

Authors:  Nicholas Kitchin; Shon A Remich; James Peterson; Yahong Peng; William C Gruber; Kathrin U Jansen; Michael W Pride; Annaliesa S Anderson; Charles Knirsch; Chris Webber
Journal:  Clin Infect Dis       Date:  2020-01-01       Impact factor: 9.079

9.  Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection.

Authors:  Eric R Littmann; Jung-Jin Lee; Joshua E Denny; Zahidul Alam; Jeffrey R Maslanka; Isma Zarin; Rina Matsuda; Rebecca A Carter; Bože Susac; Miriam S Saffern; Bryton Fett; Lisa M Mattei; Kyle Bittinger; Michael C Abt
Journal:  Nat Commun       Date:  2021-02-02       Impact factor: 14.919

10.  Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection.

Authors:  Joseph P Zackular; Jessica L Moore; Ashley T Jordan; Lillian J Juttukonda; Michael J Noto; Maribeth R Nicholson; Jonathan D Crews; Matthew W Semler; Yaofang Zhang; Lorraine B Ware; M Kay Washington; Walter J Chazin; Richard M Caprioli; Eric P Skaar
Journal:  Nat Med       Date:  2016-09-26       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.